Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
136.64K | 1.36M | 10.25M | 9.89M | 17.12M | Gross Profit |
6.00K | 49.03K | 5.52M | 4.75M | 5.71M | EBIT |
-14.70M | -4.40M | -2.92M | -5.29M | -2.51M | EBITDA |
-17.39M | -6.29M | -1.87M | -5.15M | -2.40M | Net Income Common Stockholders |
9.07M | -17.84M | -3.47M | -5.32M | -2.54M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
308.10K | 314.00 | 1.09M | 3.12M | 5.92M | Total Assets |
104.85M | 12.53M | 3.71M | 5.77M | 9.79M | Total Debt |
3.53M | 6.76M | 1.58M | 1.25M | 627.46K | Net Debt |
3.22M | 6.76M | 489.01K | -1.87M | -5.29M | Total Liabilities |
25.78M | 11.99M | 3.37M | 2.00M | 1.11M | Stockholders Equity |
79.07M | 542.35K | 763.14K | 3.77M | 8.68M |
Cash Flow | Free Cash Flow | |||
-14.27M | -2.23M | -1.56M | -2.59M | -2.25M | Operating Cash Flow |
-14.27M | -2.23M | -1.56M | -2.57M | -2.21M | Investing Cash Flow |
27.55M | -275.72K | -427.85K | -22.60K | -37.51K | Financing Cash Flow |
-12.98M | 1.41M | -35.17K | -208.18K | 5.30M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $5.24B | 3.27 | -45.39% | 2.80% | 16.77% | -0.07% | |
48 Neutral | $25.00M | ― | -2951.24% | ― | 14.17% | 28.26% | |
47 Neutral | $20.14M | ― | 38.80% | ― | -41.98% | 88.34% | |
44 Neutral | $12.32M | ― | -30.97% | ― | -97.79% | 86.73% | |
43 Neutral | $13.54M | ― | -93.11% | ― | 85.24% | -27.93% | |
39 Underperform | $17.33M | ― | -201.88% | ― | ― | ― | |
31 Underperform | $11.84M | ― | -231.27% | ― | ― | 35.08% |
On May 22, 2025, Scienture Holdings terminated a purchase agreement with Arena Business Solutions Global SPC II, Ltd., without incurring any fees. Additionally, the company received a notice from Nasdaq on May 19, 2025, for non-compliance with the minimum bid price requirement, giving it until November 17, 2025, to rectify the situation. On May 16, 2025, CEO Suren Ajjarapu resigned, followed by President Prashant Patel on May 20, 2025. Dr. Narasimhan Mani and Dr. Shankar Hariharan were appointed as co-CEOs, with Dr. Mani also serving as President. These leadership changes are part of a planned transition.
On April 8, 2025, Scienture Holdings, Inc. announced its strategic divestiture of legacy subsidiaries Integra Pharmacy Solutions LLC, Bonum Health, Inc., and Softell, Inc. to Tollo Health, Inc. for $5 million. This move is part of a broader realignment to focus on its Branded and Specialty Pharma segment through Scienture, LLC. The divestiture aims to streamline operations, enhance efficiency, and dedicate resources to high-value product development, aligning with the company’s long-term growth strategy.
On March 17, 2025, Scienture Holdings, Inc. entered into a consulting agreement with Draper, Inc. to enhance its investor relations and business development, agreeing to pay Draper in restricted shares. The agreement aims to support Scienture’s financial strategies and market positioning. Additionally, on March 18, 2025, Scienture announced FDA approval for ArbliTM, a novel oral liquid formulation of losartan potassium, marking a significant milestone as it is the first FDA-approved liquid losartan in the U.S. This product targets hypertension and related conditions, offering a convenient alternative to existing solid formulations, and is expected to launch commercially in Q3 2025.
On March 13, 2025, Scienture Holdings appointed Eric Sherb as the new Chief Financial Officer, succeeding Prashant Patel, who will continue as President and COO. This strategic move is expected to enhance the company’s financial operations with Sherb’s extensive experience. Additionally, during the 2024 Annual Meeting held on March 10, 2025, stockholders voted on key proposals including the election of directors and ratification of the appointment of CM3 Advisory as the independent accounting firm, reflecting strong shareholder engagement and governance practices.
On March 4, 2025, Scienture Holdings, Inc. entered into an Exclusive Commercial and Supply Agreement with Summit Biosciences Inc., a subsidiary of Kindeva Drug Delivery L.P., granting Scienture exclusive rights to commercialize REZENOPY® (Naloxone HCl Nasal Spray 10mg) in the United States. This agreement allows Scienture to price, launch, and market the product, which is intended to combat opioid overdoses. The collaboration with Kindeva, which will handle manufacturing, aligns with Scienture’s mission to provide innovative treatment solutions and represents a strategic step in advancing public health initiatives. The agreement includes a joint steering committee to oversee activities and requires Scienture to make milestone and profit-sharing payments to Kindeva.